Table 1.

Methylation status of ZNF667-AS1 in LSCC tissues

Group	N	Methylation frequency
		Region 1		Region 2		Region 3
		n (%)	P	n (%)	P	n (%)	P
Age
<60	13	8 (61.5)	1.0	8 (61.5)	0.473	10 (76.9)	0.2673
≥ 60	19	12 (63.2)		8 (42.1)		10 (52.6)
Smoking
Positive	27	18 (66.7)	0.338	14 (51.9)	1.0	18 (66.7)	0.338
Negative	5	2 (40.0)		2 (0.4)		2 (40.0)
Drinking
Positive	19	11 (57.9)	0.713	9 (47.4)	1.0	14 (73.7)	0.150
Negative	13	9 (69.2		7 (53.8)		6 (46.2)
Pathological differentiation
Well	15	9 (60.0)	1.0	4 (26.7)	0.032	7 (46.7)	0.144
Moderate/poor	17	11 (64.7)		12 (70.6)		13 (76.5)
TNM stage
I + II	14	11 (78.6)	0.147	8 (57.1)	0.722	10 (71.4)	0.471
III + IV	18	9 (50.0)		8 (44.4)		10 (55.6)
LN metastasis
Positive	12	7 (58.3)	0.734	7 (58.3)	0.716	7 (58.3)	0.724
Negative	20	13 (65.0)		9 (45.0)		13 (65.0)
Tissues
Tumor	32	20 (62.5)	< 0.001	16 (50.0)	< 0.001	20 (62.5)	< 0.001
Normal	32	3 (9.3)		1 (3.1)		4 (12.5)

In 32 tumor tissues, hypermethylation of ZNF667-AS1 was associated with moderate/poor pathological differentiation. Comparing the tumor tissues with normal tissues of LSCC, the rate of hypermethylation was significantly higher in tumor tissues in all of the three regions of CpG island